Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer

Molecular Therapy Oncolytics

Volumn 1, Issue , 2014, Pages 14004-

  Zamarin, Dmitriy ^a,b   Wolchok, Jedd D ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Weill Cornell Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 LIGAND; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOMODULATING AGENT; ONCOLYTIC VIRUS; PROGRAMMED DEATH 1 RECEPTOR;

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER INHIBITION; CELL DEATH; CLINICAL TRIAL (TOPIC); DRUG POTENTIATION; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR RESISTANCE; UPREGULATION;

EID: 85006117102     PISSN: None     EISSN: 23727705     Source Type: Journal    
DOI: 10.1038/mto.2014.4     Document Type: Review

References (122)

1. Hanahan, D and Weinberg, RA (2011). Hallmarks of cancer: the next generation. Cell 144: 646-674.
2. Boon, T, Coulie, PG, Van den Eynde, BJ and van der Bruggen, P (2006). Human T cell responses against melanoma. Annu Rev Immunol 24: 175-208.
3. Segal, NH, Parsons, DW, Peggs, KS, Velculescu, V, Kinzler, KW, Vogelstein, B et al. (2008). Epitope landscape in breast and colorectal cancer. Cancer Res 68: 889-892.
4. Mellman, I and Steinman, RM (2001). Dendritic cells: specialized and regulated antigen processing machines. Cell 106: 255-258.
5. Trombetta, ES and Mellman, I (2005). Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 23: 975-1028.
6. de Chaisemartin, L, Goc, J, Damotte, D, Validire, P, Magdeleinat, P, Alifano, M et al. (2011). Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res 71: 6391-6399.
7. Goc, J, Fridman, WH, Sautes-Fridman, C and Dieu-Nosjean, MC (2013). Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunology 2: e26836.
8. Palucka, K, Banchereau, J and Mellman, I (2010). Designing vaccines based on biology of human dendritic cell subsets. Immunity 33: 464-478.
9. Harlin, H, Meng, Y, Peterson, AC, Zha, Y, Tretiakova, M, Slingluff, C et al. (2009). Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 69: 3077-3085.
10. Franciszkiewicz, K, Boissonnas, A, Boutet, M, Combadiere, C and Mami-Chouaib, F (2012). Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res 72: 6325-6332.
11. Zitvogel, L, Tesniere, A and Kroemer, G (2006). Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6: 715-727.
12. Motz, GT and Coukos, G (2013). Deciphering and reversing tumor immune suppression. Immunity 39: 61-73.
13. Chen, DS and Mellman, I (2013). Oncology meets immunology: the cancer-immunity cycle. Immunity 39: 1-10.
14. Wolchok, JD, Kluger, H, Callahan, MK, Postow, MA, Rizvi, NA, Lesokhin, AM et al. (2013). Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369: 122-133.
15. Hamid, O, Robert, C, Daud, A, Hodi, FS, Hwu, WJ, Kefford, R et al. (2013). Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369: 134-144.
16. Curti, BD, Kovacsovics-Bankowski, M, Morris, N, Walker, E, Chisholm, L, Floyd, K et al. (2013). OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res 73: 7189-7198.
17. Robert, C, Thomas, L, Bondarenko, I, O'Day, S, M D, JW, Garbe, C et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526.
18. Hodi, FS, O'Day, SJ, McDermott, DF, Weber, RW, Sosman, JA, Haanen, JB et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
19. Sznol, M, Hodi, FS, Margolin, K, McDermott, DF, Ernstoff, MS, Kirkwood, JM et al. (2008). Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). 2008 ASCO Annual Meeting. Chicago, IL. pp. 3007.
20. Topalian, SL, Hodi, FS, Brahmer, JR, Gettinger, SN, Smith, DC, McDermott, DF et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454.
21. Beatty, GL, Chiorean, EG, Fishman, MP, Saboury, B, Teitelbaum, UR, Sun, W et al. (2011). CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331: 1612-1616.
22. Zitvogel, L and Kroemer, G (2009). Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects. J Clin Invest 119: 2127-2130.
23. van Elsas, A, Hurwitz, AA and Allison, JP (1999). Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190: 355-366.
24. Mellman, I, Coukos, G and Dranoff, G (2011). Cancer immunotherapy comes of age. Nature 480: 480-489.
25. Russell, SJ, Peng, KW and Bell, JC (2012). Oncolytic virotherapy. Nat Biotechnol 30: 658-670.
26. Cattaneo, R, Miest, T, Shashkova, EV and Barry, MA (2008). Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 6: 529-540.
27. Lorence, RM, Roberts, MS, O'Neil, JD, Groene, WS, Miller, JA, Mueller, SN et al. (2007). Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug Targets 7: 157-167.
28. Andtbacka, RHI, Collichio, FA, Amatruda, T, Senzer, NN, Chesney, J, Delman, KA et al. (2013). OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol 31: suppl; abstr LBA9008.
29. Heo, J, Reid, T, Ruo, L, Breitbach, CJ, Rose, S, Bloomston, M et al. (2013). Randomized dosefinding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 19: 329-336.
30. Tong, AW, Senzer, N, Cerullo, V, Templeton, NS, Hemminki, A and Nemunaitis, J (2012). Oncolytic viruses for induction of anti-tumor immunity. Curr Pharm Biotechnol 13: 1750-1760.
31. Bauzon, M and Hermiston, T (2014). Armed therapeutic viruses-a disruptive therapy on the horizon of cancer immunotherapy. Front Immunol 5: 74.
32. Steinman, RM, Turley, S, Mellman, I and Inaba, K (2000). The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 191: 411-416.
33. Frebel, H, Nindl, V, Schuepbach, RA, Braunschweiler, T, Richter, K, Vogel, J et al. (2012). Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. J Exp Med 209: 2485-2499.
34. Secchiero, P and Zauli, G (2008). The puzzling role of TRAIL in endothelial cell biology. Arterioscler Thromb Vasc Biol 28: e4; author reply e5-e4; author reply e6.
35. Mazanet, MM and Hughes, CC (2002). B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 169: 3581-3588.
36. Zang, X, Sullivan, PS, Soslow, RA, Waitz, R, Reuter, VE, Wilton, A et al. (2010). Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 23: 1104-1112.
37. Gabrilovich, DI and Nagaraj, S (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174.
38. Facciabene, A, Motz, GT and Coukos, G (2012). T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 72: 2162-2171.
39. Whiteside, TL (2006). Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16: 3-15.
40. Chang, CC, Campoli, M and Ferrone, S (2005). Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. Adv Cancer Res 93: 189-234.
41. Kryczek, I, Zou, L, Rodriguez, P, Zhu, G, Wei, S, Mottram, P et al. (2006). B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203: 871-881.
42. Whiteside, TL (2002). Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol 12: 43-50.
43. Munn, DH and Mellor, AL (2004). IDO and tolerance to tumors. Trends Mol Med 10: 15-18.
44. Cipponi, A, Wieers, G, van Baren, N and Coulie, PG (2011). Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why Cancer Immunol Immunother 60: 1153-1160.
45. Clarke, B, Tinker, AV, Lee, CH, Subramanian, S, van de Rijn, M, Turbin, D et al. (2009). Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 22: 393-402.
46. Fridman, WH, Pages, F, Sautes-Fridman, C and Galon, J (2012). The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12: 298-306.
47. Gajewski, TF, Louahed, J and Brichard, VG (2010). Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 16: 399-403.
48. Hamid, O, Schmidt, H, Nissan, A, Ridolfi, L, Aamdal, S, Hansson, J et al. (2011). A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9: 204.
49. Ji, RR, Chasalow, SD, Wang, L, Hamid, O, Schmidt, H, Cogswell, J et al. (2012). An immuneactive tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 61: 1019-1031.
50. Lee, HE, Chae, SW, Lee, YJ, Kim, MA, Lee, HS, Lee, BL et al. (2008). Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer 99: 1704-1711.
51. Lurquin, C, Lethe, B, De Plaen, E, Corbiere, V, Theate, I, van Baren, N et al. (2005). Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 201: 249-257.
52. Oble, DA, Loewe, R, Yu, P and Mihm, MC Jr (2009). Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 9: 3.
53. Pages, F, Berger, A, Camus, M, Sanchez-Cabo, F, Costes, A, Molidor, R et al. (2005). Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353: 2654-2666.
54. Ruffini, E, Asioli, S, Filosso, PL, Lyberis, P, Bruna, MC, Macri, L et al. (2009). Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg 87: 365-71; discussion 371.
55. Sheu, BC, Kuo, WH, Chen, RJ, Huang, SC, Chang, KJ and Chow, SN (2008). Clinical significance of tumor-infiltrating lymphocytes in neoplastic progression and lymph node metastasis of human breast cancer. Breast 17: 604-610.
56. Galon, J, Costes, A, Sanchez-Cabo, F, Kirilovsky, A, Mlecnik, B, Lagorce-Pages, C et al. (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
57. Galon, J, Pages, F, Marincola, FM, Angell, HK, Thurin, M, Lugli, A et al. (2012). Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 10: 205.
58. Spranger, S, Spaapen, RM, Zha, Y, Williams, J, Meng, Y, Ha, TT et al. (2013). Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 5: 200ra116.
59. Rosenberg, SA and Dudley, ME (2009). Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21: 233-240.
60. Chen, L and Flies, DB (2013). Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13: 227-242.
61. Leach, DR, Krummel, MF and Allison, JP (1996). Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736.
62. Dong, H, Strome, SE, Salomao, DR, Tamura, H, Hirano, F, Flies, DB et al. (2002). Tumorassociated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800.
63. Iwai, Y, Ishida, M, Tanaka, Y, Okazaki, T, Honjo, T and Minato, N (2002). Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99: 12293-12297.
64. Brahmer, JR, Tykodi, SS, Chow, LQ, Hwu, WJ, Topalian, SL, Hwu, P et al. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465.
65. Garon, EB, Balmanoukian, A, Hamid, O, Hui, R, Gandhi, L, Leighl, N et al. (2013). Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC). 15th World Conference on Lung Cancer. Sydney, Australia
66. Berger, R, Rotem-Yehudar, R, Slama, G, Landes, S, Kneller, A, Leiba, M et al. (2008). Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14: 3044-3051.
67. Schaer, DA, Hirschhorn-Cymerman, D and Wolchok, JD (2014). Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J Immunother Cancer 2: 7.
68. Fuertes, MB, Kacha, AK, Kline, J, Woo, SR, Kranz, DM, Murphy, KM et al. (2011). Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 208: 2005-2016.
69. Burnette, BC, Liang, H, Lee, Y, Chlewicki, L, Khodarev, NN, Weichselbaum, RR et al. (2011). The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 71: 2488-2496.
70. Diamond, MS, Kinder, M, Matsushita, H, Mashayekhi, M, Dunn, GP, Archambault, JM et al. (2011). Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208: 1989-2003.
71. Bianchi, ME (2007). DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81: 1-5.
72. Janeway, CA Jr and Medzhitov, R (2002). Innate immune recognition. Annu Rev Immunol 20: 197-216.
73. Kono, H and Rock, KL (2008). How dying cells alert the immune system to danger. Nat Rev Immunol 8: 279-289.
74. Krysko, DV, Agostinis, P, Krysko, O, Garg, AD, Bachert, C, Lambrecht, BN et al. (2011). Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol 32: 157-164.
75. Takeuchi, O and Akira, S (2010). Pattern recognition receptors and inflammation. Cell 140: 805-820.
76. Tesniere, A, Panaretakis, T, Kepp, O, Apetoh, L, Ghiringhelli, F, Zitvogel, L et al. (2008). Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 15: 3-12.
77. Devaud, C, John, LB, Westwood, JA, Darcy, PK and Kershaw, MH (2013). Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2: e25961.
78. Lou, Y, Liu, C, Lizee, G, Peng, W, Xu, C, Ye, Y et al. (2011). Antitumor activity mediated by CpG: the route of administration is critical. J Immunother 34: 279-288.
79. Amos, SM, Pegram, HJ, Westwood, JA, John, LB, Devaud, C, Clarke, CJ et al. (2011). Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol Immunother 60: 671-683.
80. Mangsbo, SM, Sandin, LC, Anger, K, Korman, AJ, Loskog, A and Totterman, TH (2010). Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother 33: 225-235.
81. Houot, R and Levy, R (2009). T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 113: 3546-3552.
82. Corrales, L, Woo, SR and Gajewski, TF (2013). Extremely potent immunotherapeutic activity of a STING agonist in the B16 melanoma model in vivo. J Immunother Cancer 1 (suppl. 1): O15.
83. Dubrot, J, Palazon, A, Alfaro, C, Azpilikueta, A, Ochoa, MC, Rouzaut, A et al. (2011). Intratumoral injection of interferon-a and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy. Int J Cancer 128: 105-118.
84. Tedcastle, A, Cawood, R, Di, Y, Fisher, KD and Seymour, LW (2012). Virotherapy-cancer targeted pharmacology. Drug Discov Today 17: 215-220.
85. Lindenmann, J and Klein, PA (1967). Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. J Exp Med 126: 93-108.
86. Guo, ZS, Liu, Z and Bartlett, DL (2014). Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity. Front Oncol 4: 74.
87. Zamarin, D and Palese, P (2012). Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol 7: 347-367.
88. Batliwalla, FM, Bateman, BA, Serrano, D, Murray, D, Macphail, S, Maino, VC et al. (1998). A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med 4: 783-794.
89. Cassel, WA and Murray, DR (1992). A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother 9: 169-171.
90. Cassel, WA and Murray, DR (1988). Treatment of stage II malignant melanoma patients with a Newcastle disease virus oncolysate. Nat Immun Cell Growth Regul 7: 351-352.
91. Schirrmacher, V and Fournier, P (2009). Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol Biol 542: 565-605.
92. Melcher, A, Parato, K, Rooney, CM and Bell, JC (2011). Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 19: 1008-1016.
93. Zamarin, D, Holmgaard, RB, Subudhi, SK, Park, JS, Mansour, M, Palese, P et al. (2014). Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 6: 226ra32.
94. Ni, J, Galani, IE, Cerwenka, A, Schirrmacher, V and Fournier, P (2011). Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity. Vaccine 29: 1185-1193.
95. Fournier, P, Arnold, A, Wilden, H and Schirrmacher, V (2012). Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. Int J Oncol 40: 840-850.
96. Kaufman, HL, Kim, DW, DeRaffele, G, Mitcham, J, Coffin, RS and Kim-Schulze, S (2010). Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17: 718-730.
97. Andarini, S, Kikuchi, T, Nukiwa, M, Pradono, P, Suzuki, T, Ohkouchi, S et al. (2004). Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res 64: 3281-3287.
98. Calmels, B, Paul, S, Futin, N, Ledoux, C, Stoeckel, F and Acres, B (2005). Bypassing tumorassociated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L. Cancer Gene Ther 12: 198-205.
99. Kim, HS, Kim-Schulze, S, Kim, DW and Kaufman, HL (2009). Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand. Cancer Res 69: 8516-8525.
100. Kaufman, HL, Deraffele, G, Mitcham, J, Moroziewicz, D, Cohen, SM, Hurst-Wicker, KS et al. (2005). Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 115: 1903-1912.
101. Pesonen, S, Diaconu, I, Kangasniemi, L, Ranki, T, Kanerva, A, Pesonen, SK et al. (2012). Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res 72: 1621-1631.
102. Parviainen, S, Ahonen, M, Diaconu, I, Hirvinen, M, Karttunen, A, Vaha-Koskela, M et al. (2014). CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging. Gene Ther 21: 195-204.
103. Andtbacka, RHI, Curti, BD, Kaufman, H, Daniels, GA, Nemunaitis, JJ, Spitler, LE et al. (2014). CALM study: A phase II study of an intratumorally delivered oncolytic immunotherapeutic agent, coxsackievirus A21, in patients with stage IIIc and stage IV malignant melanoma. J Clin Oncol 32: 5s (suppl; abstr 3031).
104. Pan, PY, Zang, Y, Weber, K, Meseck, ML and Chen, SH (2002). OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol Ther 6: 528-536.
105. Gao, Y, Whitaker-Dowling, P, Griffin, JA, Barmada, MA and Bergman, I (2009). Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors. Cancer Gene Ther 16: 44-52.
106. John, LB, Howland, LJ, Flynn, JK, West, AC, Devaud, C, Duong, CP et al. (2012). Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res 72: 1651-1660.
107. Sorensen, MR, Holst, PJ, Steffensen, MA, Christensen, JP and Thomsen, AR (2010). Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. Vaccine 28: 6757-6764.
108. Kato, H, Sato, S, Yoneyama, M, Yamamoto, M, Uematsu, S, Matsui, K et al. (2005). Cell type-specific involvement of RIG-I in antiviral response. Immunity 23: 19-28.
109. Aida, K, Miyakawa, R, Suzuki, K, Narumi, K, Udagawa, T, Yamamoto, Y et al. (2014). Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-a gene therapy for pancreatic cancer. Cancer Sci 105: 159-167.
110. Puzanov, I, Milhem, MM, Andtbacka, RHI, Minor, DR, Hamid, O, Li, A, Chastain, M et al. (2014). Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol 32: 5s (suppl; abstr 9029)
111. Espenschied, J, Lamont, J, Longmate, J, Pendas, S, Wang, Z, Diamond, DJ et al. (2003). CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol 170: 3401-3407.
112. Munks, MW, Mourich, DV, Mittler, RS, Weinberg, AD and Hill, AB (2004). 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine. Immunology 112: 559-566.
113. Ko, HJ, Kim, YJ, Kim, YS, Chang, WS, Ko, SY, Chang, SY et al. (2007). A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 67: 7477-7486.
114. Sierro, SR, Donda, A, Perret, R, Guillaume, P, Yagita, H, Levy, F et al. (2011). Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur J Immunol 41: 2217-2228.
115. Kudo-Saito, C, Hodge, JW, Kwak, H, Kim-Schulze, S, Schlom, J and Kaufman, HL (2006). 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. Vaccine 24: 4975-4986.
116. Chakraborty, M, Schlom, J and Hodge, JW (2007). The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses. Cancer Immunol Immunother 56: 1471-1484.
117. Marabelle, A, Kohrt, H, Sagiv-Barfi, I, Ajami, B, Axtell, RC, Zhou, G et al. (2013). Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 123: 2447-2463.
118. Dias, JD, Hemminki, O, Diaconu, I, Hirvinen, M, Bonetti, A, Guse, K et al. (2012). Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther 19: 988-998.
119. Bridle, BW, Stephenson, KB, Boudreau, JE, Koshy, S, Kazdhan, N, Pullenayegum, E et al. (2010). Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther 18: 1430-1439.
120. Galivo, F, Diaz, RM, Thanarajasingam, U, Jevremovic, D, Wongthida, P, Thompson, J et al. (2010). Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum Gene Ther 21: 439-450.
121. Leveille, S, Goulet, ML, Lichty, BD and Hiscott, J (2011). Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation. J Virol 85: 12160-12169.
122. Zhang, L, Bridle, BW, Chen, L, Pol, J, Spaner, D, Boudreau, JE et al. (2013). Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responses. Blood 121: 2432-2439.